Between 2015 and 2019, methamphetamine-involved overdose deaths among Veterans increased by 300 percent. That figure, drawn from peer-reviewed analysis published in Drug and Alcohol Dependence, reflects a crisis that developed largely out of public view. While the opioid epidemic dominated headlines, a parallel stimulant crisis was building in the veteran population, one that presents distinct clinical challenges because, unlike opioid or alcohol dependence, there is no FDA-approved medication to treat it.
Meth Use in the Veteran Population: What the Data Shows
Service members use methamphetamine at rates that exceed civilian populations, particularly in the western United States and Alaska, where meth supply chains have historically been most robust. SAMHSA’s National Survey on Drug Use and Health consistently documents higher rates of stimulant use among veterans than age-matched civilians, with combat-deployed veterans showing the highest rates.
The demographic profile of veterans with methamphetamine use disorder has shifted over the past decade. Earlier data showed meth use concentrated among younger veterans, particularly those who served in the Army and Marine Corps in high-combat roles. Current data shows a broader distribution across age groups and service branches, reflecting the changing character of the meth supply: modern methamphetamine is more potent, cheaper, and more widely available than at any prior point in American history.
Illicitly manufactured methamphetamine today is nearly universally produced using the P2P (phenyl-2-propanone) synthesis method, which produces both d-methamphetamine and l-methamphetamine in roughly equal proportions. The d-isomer produces the stimulant and euphoric effects. The l-isomer has primarily peripheral cardiovascular effects. P2P meth is structurally different from the pseudoephedrine-based meth that dominated before precursor controls were implemented, and clinical observations suggest it produces more severe psychiatric symptoms, including psychosis, paranoia, and cognitive impairment, at earlier stages of use.
For veterans in Alaska, methamphetamine availability is particularly acute. Alaska has consistently ranked among the highest states for meth-related deaths and hospitalizations, and the cost of meth relative to other drugs in rural Alaska communities makes it a common choice for veterans managing untreated pain and trauma with inadequate access to clinical services. Our resource on meth addiction in Alaska Veterans covers the geographic dimensions of this crisis in greater depth.
For a broader view of how substance use disorders manifest in the veteran population, see our resource on military substance abuse in Veterans.
Why Meth Appeals to Veterans Managing Fatigue and PTSD
Understanding why methamphetamine becomes a Service members’ drug of choice requires understanding what it does neurobiologically, and how that maps to the specific suffering veterans carry.
Methamphetamine causes a massive, sustained release of dopamine in the nucleus accumbens, the brain’s primary reward circuit. It produces intense euphoria, dramatically elevated energy, prolonged alertness, reduced need for sleep, enhanced confidence, and suppressed appetite. For a veteran managing PTSD-related hypervigilance, the inability to relax or feel pleasure, and crushing fatigue from chronic sleep disruption, meth provides temporary neurochemical relief that is subjectively extraordinary.
PTSD is characterized by anhedonia, the inability to experience pleasure from activities that were previously rewarding. This is not laziness or depression in the conventional sense; it is a neurobiological consequence of trauma-induced changes to the dopaminergic reward system. Meth directly addresses anhedonia by flooding the reward system with dopamine. The relief veterans experience is real and potent, which is precisely why the drug becomes compulsive: nothing else in their environment produces that magnitude of neurochemical response.
Combat hypervigilance, the persistent state of threat detection that combat deployment trains into the nervous system, produces chronic fatigue because the body cannot sustain that level of sympathetic activation indefinitely. Veterans managing hypervigilance often report exhaustion that sleep does not resolve, because sleep quality is itself disrupted by PTSD. Meth eliminates fatigue pharmacologically, enabling veterans to function, work, and engage socially in ways they cannot without it. The relief from this borrowed energy is compelling enough to override awareness of the long-term consequences.
Military culture also plays a role. The premium placed on performance, endurance, and the suppression of weakness creates a framework in in which meth, a drug that removes fatigue and produces confidence, aligns with military values in a superficially seductive way. Stimulant use has historical roots in military culture: amphetamines were issued to soldiers in World War II, Korea, and Vietnam, and contemporary military pilots are sometimes prescribed stimulants for long missions. This cultural familiarity lowers the psychological barrier to meth use.
How Meth Damages the Brain Differently Than Other Substances
Methamphetamine produces neurotoxic damage through mechanisms distinct from other addictive substances. While opioids and alcohol primarily alter receptor sensitivity through downregulation and upregulation, meth causes direct structural damage to dopamine-producing neurons.
Meth causes neurons to release dopamine in quantities far exceeding normal firing, and this excess dopamine itself causes oxidative damage to the neurons that produce it. Neuroimaging research published in Neuropharmacology demonstrates that heavy meth users show significant reductions in dopamine transporter density in the striatum and prefrontal cortex, structures critical to reward processing, motivation, impulse control, and decision-making. These reductions persist for years after cessation of use, and in some cases are permanent.
The clinical consequences of this neurotoxicity include:
- Prolonged anhedonia during early recovery: Because meth damages the neurons responsible for natural dopamine production, veterans in early meth recovery often experience weeks to months of profound anhedonia, an inability to experience pleasure from anything. This is not depression in the traditional sense; it is neurochemical depletion following massive over-stimulation. The duration and severity of this anhedonia is the primary driver of relapse in the early recovery period.
- Cognitive impairment: Meth damages the prefrontal cortex systems involved in working memory, executive function, and impulse control. Veterans with significant meth use histories show cognitive deficits that can persist for 12–18 months after cessation. These deficits affect their ability to engage with therapy, maintain schedules, and make consistent recovery-oriented decisions.
- Psychosis: Meth-induced psychosis, characterized by paranoia, hallucinations, and disorganized thinking, can occur during active use and in withdrawal. In Service members who already carry combat-related hypervigilance and trauma, meth psychosis can be particularly severe and difficult to distinguish from PTSD-related dissociation without careful clinical assessment. Psychosis typically resolves within days to weeks of abstinence, though some veterans experience persistent psychotic symptoms, particularly if they carry underlying vulnerability to psychotic disorders.
- Dental and cardiovascular damage: Meth causes severe dental deterioration (“meth mouth”) through a combination of dry mouth, teeth grinding, and reduced attention to oral hygiene. It produces significant cardiovascular stress (hypertension, tachycardia, arrhythmia) that can result in heart attack or stroke during active use.
For veterans who have also sustained traumatic brain injuries, meth’s neurotoxic effects compound the existing neurological damage, producing cognitive and psychiatric presentations that are particularly complex to treat. Clinical staff at Hope Valley Health and Wellness are trained to assess and manage this co-occurring complexity.
The Treatment Challenge: No Approved MAT for Meth
The single most important clinical fact about methamphetamine treatment is that there is currently no FDA-approved medication for methamphetamine use disorder. Opioid use disorder has buprenorphine, methadone, and naltrexone as pharmacological scaffolding for recovery, and alcohol use disorder has naltrexone, acamprosate, and disulfiram. Meth treatment relies entirely on behavioral intervention.
This is not for lack of scientific effort. More than 40 candidate medications have been studied in clinical trials for methamphetamine use disorder, including bupropion, modafinil, naltrexone, ibudilast, and various combinations. A landmark 2021 trial published in the New England Journal of Medicine found that the combination of bupropion and extended-release naltrexone significantly reduced meth use in participants, representing the closest thing to an evidence-based medication protocol currently available, though neither medication is specifically FDA-approved for this indication.
The absence of approved MAT for meth has two important implications for Service member treatment:
First, the intensity of behavioral treatment matters more in meth recovery than in any other substance use disorder. Without pharmacological management of craving and withdrawal, the behavioral and peer interventions become the primary therapeutic engine. This means the quality of the clinical team, the structure of the residential environment, and the strength of the peer community are more consequential in meth treatment than in opioid or alcohol treatment.
Second, withdrawal from meth, while not medically dangerous in the way that opioid or alcohol withdrawal can be, produces a prolonged period of profound dysphoria, fatigue, hypersomnia, and anhedonia that is experienced by many veterans as worse than the active addiction. Managing patients through this withdrawal period without pharmacological support requires skilled clinical management of expectations, sleep hygiene, nutrition, physical activity, and therapeutic engagement. Residential treatment provides the structure that makes this possible.
For veterans and Families Seeking Treatment
Hope Valley Health and Wellness accepts TRICARE and handles prior authorization, benefit verification, and travel coordination for veterans across Alaska and the lower 48. Benefit verification is free and takes one business day.
Behavioral Treatments That Work for Meth Dependency
Despite the absence of approved pharmacotherapy, methamphetamine use disorder is treatable. The evidence base for behavioral treatments is substantial, and outcomes in well-designed programs are comparable to those achieved for opioid and alcohol use disorders with MAT.
Contingency Management (CM): CM is the most rigorously evidence-supported behavioral treatment for methamphetamine use disorder. It uses tangible incentives, typically vouchers redeemable for goods and services, to reinforce negative drug tests and treatment attendance. Meta-analyses published in Drug and Alcohol Dependence consistently show that CM produces significantly higher abstinence rates than treatment without incentive structures. The VA has implemented CM programs in VA facilities following extensive research, and CARF-accredited facilities are increasingly incorporating CM protocols.
Cognitive Behavioral Therapy (CBT): CBT for meth use disorder focuses on identifying the triggers, thought patterns, and emotional states that precede use, and developing specific coping strategies for each. For veterans, CBT must be adapted to address the specific triggers associated with PTSD (intrusive memories, hypervigilance responses, avoidance behaviors), as these are the primary drivers of use in combat Service members. CBT delivered in a Veteran-specific program is more effective than generic CBT because it does not require Veterans to translate their experience into civilian frameworks.
The Matrix Model: The Matrix Model is a structured 16-week outpatient protocol specifically developed for stimulant use disorders. It combines CBT, motivational interviewing, family education, and 12-step participation into a comprehensive manualized program. Research funded by SAMHSA and NIDA demonstrates its effectiveness for methamphetamine dependence specifically.
Trauma-Focused Therapy: For Veterans, treating meth use disorder without treating the underlying PTSD is analogous to treating the symptom while leaving the cause in place. EMDR, Accelerated Resolution Therapy, and Cognitive Processing Therapy address the trauma-driven dysregulation that meth was functionally managing. When trauma symptoms are clinically reduced, the neurochemical imperative to self-medicate diminishes.
Physical Exercise: Research from NIDA-funded studies demonstrates that aerobic exercise reduces meth craving, improves mood during the anhedonic withdrawal phase, and supports neuroplasticity in the dopaminergic systems damaged by meth. Exercise is not an adjunct at Hope Valley; it is a core clinical component of the treatment program, particularly for Veterans whose military background makes physical activity both culturally resonant and neurobiologically beneficial.
Peer Recovery Support: Veterans in meth recovery benefit from peer communities composed of other Veterans who understand the specific cultural context of military substance use: the functional use, the performance motivation, the shame around seeking help. Veteran-specific peer support communities provide a framework for accountability and connection that is simply unavailable in general-population recovery settings.
For Veterans with co-occurring disorders alongside meth use, which includes the majority of veterans seeking treatment, see our resource on co-occurring disorders in Veterans.
The Alaska Context: Meth in the Veteran Community
Alaska presents a distinct meth landscape that requires specific clinical awareness. The state consistently ranks among the highest in the nation for methamphetamine-related criminal justice involvement, hospitalizations, and deaths. In rural Alaska communities, the isolation that characterizes daily life intersects with limited clinical resources to create conditions in which meth use can progress to severe dependence before any treatment intervention occurs.
For Alaska Veterans, the geographic barriers to treatment are acute. The VA Alaska Healthcare System is concentrated in Anchorage, leaving Veterans in the Mat-Su Valley, the Interior, and rural communities with limited access to VA services. Community mental health resources in smaller communities are often staffed by generalists without specific addiction or trauma training. The consequence is that Alaska Veterans frequently present to treatment with longer histories of use and more severe dependence than Veterans in states with denser clinical infrastructure.
Hope Valley Health and Wellness, located in Wasilla, Alaska, was established specifically to address this gap. As a CARF-accredited residential program in the Mat-Su Valley, Hope Valley provides Alaska Veterans with access to evidence-based meth treatment without requiring travel to Anchorage or the lower 48. TRICARE covers residential treatment at Hope Valley, and the admissions team manages travel coordination for Veterans coming from rural communities across Alaska.
The clinical staff at Hope Valley includes individuals with direct experience in the Alaska Veteran community and an understanding of how rural Alaska’s social environment (the cultural role of substances in managing isolation, limited employment options, and geographic separation from family systems) shapes addiction and recovery. Treatment that does not account for the post-discharge environment a Veteran is returning to cannot adequately prepare that Veteran for sustained recovery.
For Veterans considering the choice between residential and outpatient treatment for meth dependency, our resource on residential vs. outpatient treatment for Veterans provides a clinical framework for that decision.
Methamphetamine use disorder is difficult to treat, but it is treatable. The absence of approved pharmacotherapy makes the quality of the clinical program more important, not less. Veterans who engage with evidence-based residential treatment, trauma-focused therapy, peer community, and structured aftercare achieve recovery outcomes that match those seen with pharmacologically assisted treatments for other substances. The path is harder. The destination is the same.